V2ACT immunotherapy - Genelux Corporation
Latest Information Update: 15 Jan 2024
At a glance
- Originator Genelux Corporation
- Developer Genelux Corporation; V2ACT Therapeutics
- Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunomodulators; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pancreatic cancer